Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740141 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| SCHEMBL1609328 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19638092 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| Hydrochloric Acid SCHEMBL613075 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| SCHEMBL13740434 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL934458 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL13739335 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| Hydrochloric Acid SCHEMBL28596153 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL3842738 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1SLC6A1CYP1A2CYP2D6 | |
| Aniline SCHEMBL27948912 | 0.85 | ALDH1A1 (0.55) | ALDH1A1SLC6A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8222425-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222425-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-2468749-A1 | Process for the preparation of Linagliptin | Dipharma Francis S.r.l. (IT) | 2012-06-27 | — | — | EP | disclosed |
| US-RE43390-E1 | Pleuromutilin derivatives as antimicrobials | GLAXOSMITHKLINE LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1578723-A4 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | UNIV MICHIGAN STATE (US) | 2006-11-02 | — | — | EP | disclosed |
| US-RE39128-E1 | ANTIBACTERIA DRUG; RESPIRATORY SYSTEM DISORDERS; OTITIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-06-13 | — | — | US | disclosed |
| EP-1578723-A3 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2005-10-20 | — | — | EP | disclosed |
| EP-1578723-A2 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1028961-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1452534-A1 | PLEUROMUTLIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003106413-A2 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | disclosed |
| EP-1028961-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021855-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CNR2, CNR1, FAAH | SMN1; SMN2 2897/4885ALDH1A1 2486/4885S1PR5 24/4885 |
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP8, DPP7 | SMN1; SMN2 2232/4885ALDH1A1 538/4885S1PR5 2217/4885 |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | SMN1; SMN2 4302/4885ALDH1A1 3965/4885S1PR5 3284/4885 |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | SMN1; SMN2 2827/4885ALDH1A1 1528/4885S1PR5 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.